Stay Tuned: ASCO 2010 is Just Around the Corner

Article

The theme of this year’s ASCO meeting is “advancing quality through innovation.” As always, the vast scope of this annual meeting is daunting. In order to give our readers an ongoing analysis of ASCO ’10, The Oncology Forum will be posting daily from Chicago, parsing out the best sessions and most relevant clinical information.

The theme of this year’s annual  ASCO meeting is “advancing quality through innovation.” As always, the vast scope of this international meeting is daunting. In order to give our readers an ongoing analysis of ASCO ’10, The Oncology Forum will be posting daily from Chicago, parsing out the best sessions and most relevant clinical information. 

The Forum will also highlight the most important practice management information, nuts & bolts tips that will help your practice’s bottom line and analysis of how Obama’s healthcare bill will impact the ability to treat your patients in the brave new world of comparative effectiveness research (CER) and steep Medicare cuts.


Here’s a new feature from this year’s meeting:

Trials in Progress Poster Session
 

The new Trials in Progress Poster Session will facilitate awareness of and dialogue about open, ongoing clinical trials. It differs from other Poster Sessions in that:

--outcomes data or results are not included,

--the goal is to promote discussion among trial investigators, to encourage recruitment of new investigators or sites, and to stimulate discussion of successor or confirmatory trials, 

--the focus is on the background of the science behind the trial, and preclinical or earlier-phase data (preferably with references) is encouraged.
 

Also, watch The Forum for exclusive interviews from the meeting's top presenters.

Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content